期刊
MOLECULAR GENETICS AND METABOLISM
卷 88, 期 3, 页码 201-207出版社
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.ymgme.2006.02.004
关键词
betaine; homocysteine; homocystinuria; remethylation disorders; coronary artery disease; methionine
资金
- NHGRI NIH HHS [R01-HG02085] Funding Source: Medline
- NIGMS NIH HHS [T32 GM7748] Funding Source: Medline
- PHS HHS [1U22MC03959] Funding Source: Medline
Elevation of homocysteine is implicated in multiple medical conditions, including classical homocystinuria, a variety of remethylation disorders, and most recently in coronary artery disease. Betaine is a methyl donor agent that is beneficial in lowering homocysteine through the remethylation of methionine. Betaine therapy alone has been shown to prevent vascular events in homocystinuria and may have clinical benefits in other hyperhomocysteinemic disorders when used as adjunctive therapy. Betaine does raise the methionine level and cerebral edema has occurred when plasma methionine exceeds 1000 mu mol/L. Thus the plasma methionine as well as homocysteine must be monitored in patients receiving betaine. (c) 2006 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据